MedTrace Logo

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02745704 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-01-15

No results posted yet for this study

Summary

As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.

Conditions

Interventions

DRUG

Peginterferon alfa

peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Nanchang University

    collaborator OTHER

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • First People's Hospital, Shunde China

    collaborator OTHER

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Tang-Du Hospital

    collaborator OTHER

  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER

  • Yuebei People's Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02745704 on ClinicalTrials.gov